| Project/Area Number |
25670433
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Metabolomics
|
|---|
| Research Institution | Osaka University |
|---|
Principal Investigator |
MORISHITA Ryuichi 大阪大学, 医学(系)研究科(研究院), 寄附講座教授 (40291439)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
NAKAGAMI Hironori 大阪大学, 大学院医学系研究科, 教授 (20325369)
|
|---|
| Project Period (FY) |
2013-04-01 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2014: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2013: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Keywords | ワクチン / 糖尿病 / 脂質異常症 |
|---|
| Outline of Final Research Achievements |
We developed a dipeptidyl peptidase 4 (DPP4)-targeted immune therapy for the prevention and treatment of type 2 diabetes mellitus and a Lp(a)-targeted immune therapy for the treatment of high Lp(a) patients. Immunization with the DPP4 vaccine in C57BL/6J mice successfully increased DPP4 titer and inhibited plasma DPP4 activity. Moreover, this elevated titer was sustained for 3 month. In mice fed a high-fat diet, DPP4 vaccination resulted in improved postprandial glucose excursions and insulin sensitivity and, in the diabetic KK-Ay and db/db mice strains, DPP4 vaccination significantly reduced glucose excursions and increased both plasma insulin and pancreatic insulin content.Thus, this DPP4 vaccine may provide a therapeutic alternative for patients with diabetes.
|
